Novo Nordisk falls as Ozempic, Wegovy targeted in Medicare price negotiations
Investing.com -- Shares of Novo Nordisk (NYSE: NVO) fell 3.6% on Friday after the U.S. Department of Health and Human Services (HHS) announced that Ozempic and Wegovy are among 15 medications selected for Medicare price negotiations under the Inflation Reduction Act.
The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a ...
Medicare has announced 15 new drugs up for price negotiations, set to begin in the next several months with top drugmakers, ...
Click in for more news from The Hill{beacon} Health Care Health Care The Big Story Biden adds Ozempic to list for Medicare price negotiationIn one of its last actions, the Biden ...
Drugs like Ozempic and Wegovy are now costing Connecticut taxpayers about $60 million this year and that figure could rise ...
A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...
The company's weight-loss drugs have been shown to be more effective than rival Ozempic ... the stock trades at a forward price-to-earnings (P/E) ratio of 35 times next year's analyst ...
The post from Musk called himself "Ozempic ... Price Action: Novo Nordisk stock trades at $87.56 at the time of writing. The stock is down 14% year-to-date in 2024 and up 200.6% over the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback